MX2016011852A - Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). - Google Patents
Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).Info
- Publication number
- MX2016011852A MX2016011852A MX2016011852A MX2016011852A MX2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A MX 2016011852 A MX2016011852 A MX 2016011852A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- seq
- methods
- amino acid
- pulmonary fibrosis
- Prior art date
Links
- 210000004072 lung Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 229940124789 MK2 inhibitor Drugs 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953438P | 2014-03-14 | 2014-03-14 | |
| PCT/US2015/020263 WO2015138784A2 (en) | 2014-03-14 | 2015-03-12 | Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011852A true MX2016011852A (es) | 2017-05-09 |
Family
ID=54067793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011852A MX2016011852A (es) | 2014-03-14 | 2015-03-12 | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705074B2 (en) | 2015-09-25 | 2020-07-07 | Cedars-Sinai Medical Center | Targeting fibroblast invasion for pulmonary fibrosis |
| WO2019070908A1 (en) | 2017-10-03 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS |
| KR20220015441A (ko) * | 2019-05-30 | 2022-02-08 | 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 | 특발성 폐 섬유증의 동물 모델, 이의 구축 방법 및 용도 |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
| US20220202852A1 (en) * | 2020-12-30 | 2022-06-30 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560200A1 (en) * | 2004-03-17 | 2005-09-22 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| WO2012142238A2 (en) * | 2011-04-12 | 2012-10-18 | Duke University | Compositions and methods for the treatment of tissue fibrosis |
| CN111110850A (zh) * | 2011-04-12 | 2020-05-08 | 莫伊莱麦屈克斯公司 | 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法 |
-
2015
- 2015-03-12 JP JP2016557276A patent/JP6655547B2/ja not_active Expired - Fee Related
- 2015-03-12 AU AU2015229251A patent/AU2015229251A1/en not_active Abandoned
- 2015-03-12 MX MX2016011852A patent/MX2016011852A/es unknown
- 2015-03-12 BR BR112016021000A patent/BR112016021000A2/pt not_active Application Discontinuation
- 2015-03-12 US US14/656,492 patent/US20150258192A1/en not_active Abandoned
- 2015-03-12 SG SG11201607627RA patent/SG11201607627RA/en unknown
- 2015-03-12 CA CA2942517A patent/CA2942517A1/en not_active Abandoned
- 2015-03-12 WO PCT/US2015/020263 patent/WO2015138784A2/en not_active Ceased
- 2015-03-12 EP EP15761995.8A patent/EP3116543A4/en not_active Withdrawn
- 2015-03-12 KR KR1020167028395A patent/KR20160124236A/ko not_active Withdrawn
- 2015-03-12 RU RU2016140332A patent/RU2016140332A/ru not_active Application Discontinuation
- 2015-03-12 CN CN201580025482.9A patent/CN106456758A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016140332A (ru) | 2018-04-16 |
| AU2015229251A1 (en) | 2016-09-22 |
| KR20160124236A (ko) | 2016-10-26 |
| EP3116543A2 (en) | 2017-01-18 |
| WO2015138784A3 (en) | 2015-10-29 |
| SG11201607627RA (en) | 2016-10-28 |
| JP2017509633A (ja) | 2017-04-06 |
| CN106456758A (zh) | 2017-02-22 |
| CA2942517A1 (en) | 2015-09-17 |
| WO2015138784A2 (en) | 2015-09-17 |
| US20150258192A1 (en) | 2015-09-17 |
| JP6655547B2 (ja) | 2020-02-26 |
| EP3116543A4 (en) | 2017-09-06 |
| RU2016140332A3 (cg-RX-API-DMAC7.html) | 2018-10-11 |
| BR112016021000A2 (pt) | 2017-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). | |
| MX2020004969A (es) | Composiciones y procedimientos para tratar cancer. | |
| NZ771547A (en) | Gip and glp-1 co-agonist compounds | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| ZA202302340B (en) | Compositions and methods for treating celiac sprue disease | |
| MX2019008949A (es) | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| WO2009052489A3 (en) | Novel inhibitors of mammalian tight junction opening | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| MX2019000346A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| MX2017008505A (es) | Composicion. | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| MX2016010852A (es) | Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. | |
| UA102274C2 (ru) | Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат |